Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
bioAffinity Technologies, Inc. SEC filings document the public-company record for a biotechnology diagnostics issuer with Nasdaq-listed common stock and tradeable warrants. The filings identify the company as an emerging growth company and smaller reporting company and include disclosures tied to CyPath® Lung, laboratory services, operating performance, and securities registration activity.
Recent filings include Form 8-K reports for financial results, Regulation FD presentation materials, product and clinical-case announcements, and annual meeting voting results. The record also covers governance matters such as director elections and equity incentive plan amendments, along with S-1 registration materials describing securities being registered and related issuer classifications.
bioAffinity Technologies reported that the Australian Patent Office has accepted its patent application AU 2019253111, titled “System and Method for Determining Lung Health.” The patent covers methods that combine flow cytometry with fluorescent probes and molecular tags that attach to specific cell types to detect cellular and molecular signatures of multiple lung diseases. The company issued a press release, attached as Exhibit 99.1.
bioAffinity Technologies (BIAF) called a Special Meeting to seek stockholder approval for multiple equity actions. The agenda includes authorizing the issuance of up to 271,500 shares upon exercise of August 2025 warrants, approving an anti-dilution reset that could raise the warrant share count by up to 365,620, and approving a similar anti-dilution reset for Series B Preferred that could add up to 131,884 conversion shares.
The Company also asks to amend its 2024 Equity Incentive Plan to increase the reserve to 750,000 shares and to authorize one or more non‑public offerings of up to 10 million shares for total consideration not exceeding $10,000,000, at discounts up to 35%, through December 31, 2026, along with related change‑of‑control approval under Nasdaq rules. Shares outstanding were 3,633,815 as of the record date. The Board recommends voting “FOR” each proposal.
bioAffinity Technologies reported it will present new research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The company’s project manager for product development, Rossella Titone, PhD, will present the poster titled “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests.”
The presentation is scheduled for October 22, 2025 at 10:20 a.m. at poster board #4324. The company attached its press release and the full poster as Exhibits 99.1 and 99.2, which are incorporated by reference.
bioAffinity Technologies (BIAF) reported a regulatory milestone. The company received a notification of allowance from the U.S. Patent and Trademark Office for a patent titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.” The patent covers a system and method for predicting the likelihood of lung cancer by analyzing patient sputum samples.
The company disclosed the news in a Form 8-K under Item 8.01 and attached a related press release as Exhibit 99.1. A notification of allowance indicates the USPTO intends to grant the patent following completion of administrative steps.
bioAffinity Technologies announced it has regained compliance with Nasdaq listing standards. A Nasdaq Hearings Panel found the company in compliance with Listing Rule 5550(a)(2) (the Minimum Bid Price Rule) and 5550(b)(1) (the Minimum Stockholders’ Equity Rule).
The company will be under a mandatory panel monitor for one year. If, during that period, it falls out of compliance with the Minimum Stockholders’ Equity Rule, it will not be granted additional time to regain compliance, though it may request a new hearing before any delisting. The company issued a press release on October 15, 2025, noting the compliance status.
bioAffinity Technologies entered into a securities purchase agreement with institutional investors for a registered direct offering of 720,000 shares of common stock. The transaction closed on October 9, 2025, providing the company with approximately $1.8 million in gross proceeds before placement fees and expenses.
WallachBeth Capital, LLC acted as exclusive placement agent and will receive a cash fee of 8.0% of the gross proceeds plus up to $75,000 of expense reimbursement. The company agreed that, until November 14, 2025, it will not issue most additional equity, and it will not enter into variable rate transactions for six months after the closing date, with the restriction on at-the-market offerings and equity lines ending on November 14, 2025. Officers and directors also signed 60‑day lock-up agreements limiting sales of company securities.
bioAffinity Technologies, Inc. filed a prospectus supplement describing a common stock offering at an offering price of $0.20 per share. The placement agent fees are $144,000.00, and the proceeds, before expenses, are $1,656,000.00. The document shows a historical net tangible book value per share of $(4.52) as of June 30, 2025, a pro forma net tangible book value per share of $0.20, and a pro forma as adjusted net tangible book value per share of $1.34, representing an $0.15 increase attributable to the offering. The disclosure also reports dilution per share to the new investor of $1.19 and lists authorized capital of 25,000,000 common shares (par value $0.007) and 20,000,000 preferred shares (par value $0.001).
bioAffinity Technologies is calling a special stockholder meeting on November 11, 2025 to approve several capital-related proposals. The company seeks authorization to issue up to 271,500 shares of common stock upon exercise of August 2025 warrants, which could provide up to approximately $2.9 million in gross proceeds if exercised for cash.
Stockholders are also asked to approve anti-dilution adjustments that could increase warrant exercise shares up to 365,620 and Series B Preferred conversion shares up to 131,884 following future lower-priced financings. Another proposal would expand the 2024 Equity Incentive Plan reserve from 66,666 to 750,000 shares, a level the board believes is needed for competitive employee and director compensation. The board recommends voting FOR all five proposals, including an adjournment authorization, and notes there were 3,633,815 common shares outstanding as of the October 3, 2025 record date.
bioAffinity Technologies, Inc. reported that sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025. The company disclosed this business update through a press release, which is furnished as an exhibit to this report.
The filing does not include detailed financial figures, but highlights growing adoption of the CyPath® Lung test as a notable operating milestone for the period.
bioAffinity Technologies, Inc. (BIAF) prospectus excerpts show a public offering priced at $2.50 per share with placement agent fees of $0.20 per share, producing proceeds before expenses of $2.30 per share and aggregate proceeds of $4,414,421.31. Historical net tangible book value per share was $0.20; the pro forma increase attributable to the offering is $0.99, producing a pro forma as-adjusted net tangible book value per share of $1.19. The filing notes Total capitalization of $(2,136,108) and references shares issuable upon conversion of 715.5 Series B Convertible Preferred shares at an initial conversion price of $6.90 per share.